NASDAQ:CRDF Cardiff Oncology Q1 2025 Earnings Report $1.24 -0.04 (-3.13%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$1.27 +0.03 (+2.42%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cardiff Oncology EPS ResultsActual EPS-$0.20Consensus EPS -$0.19Beat/MissMissed by -$0.01One Year Ago EPSN/ACardiff Oncology Revenue ResultsActual Revenue$0.11 millionExpected Revenue$0.09 millionBeat/MissBeat by +$21.00 thousandYoY Revenue GrowthN/ACardiff Oncology Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateThursday, May 8, 2025Conference Call Time4:00PM ETUpcoming EarningsCardiff Oncology's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cardiff Oncology Earnings HeadlinesBrokerages Set Cardiff Oncology, Inc. (NASDAQ:CRDF) Price Target at $7.50September 23, 2026 | americanbankingnews.comCardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from S&P Global BMI IndexSeptember 20, 2026 | marketscreener.comMTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)Analysts Issue Forecasts for CRDF Q3 EarningsSeptember 19, 2026 | americanbankingnews.comAnalysts Conflicted on These Healthcare Names: High Tide (HITI), Cardiff Oncology (CRDF) and Benitec Biopharma (BNTC)September 17, 2026 | theglobeandmail.comHC Wainwright & Co. upgrades Cardiff Oncology to buy from neutralSeptember 16, 2026 | msn.comSee More Cardiff Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiff Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiff Oncology and other key companies, straight to your email. Email Address About Cardiff OncologyCardiff Oncology (NASDAQ:CRDF) is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead investigational product is onvansertib, an oral, highly selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cell division and cancer-cell growth. Cardiff Oncology has primarily studied onvansertib in combination with existing treatments for patients with difficult-to-treat solid tumors, including KRAS-mutated metastatic colorectal cancer. The company has also evaluated the therapy in other cancers, including metastatic pancreatic cancer and certain breast cancers. Onvansertib remains investigational and has not been approved for commercial use. The company was formerly known as Trovagene, Inc. and adopted the Cardiff Oncology name in 2019 as it shifted its focus toward oncology drug development. Based in San Diego, California, Cardiff Oncology conducts its clinical development activities primarily through collaborations and clinical sites in the United States. Mark Erlander, M.D., has served as the company’s chief executive officer.View Cardiff Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
